BPC-157 and TB-500: what they are, what they are for and what is known

What BPC-157 is

BPC-157 stands for "body protection compound-157". It is a pentadecapeptide (15 amino acids) with the sequence GEPPPGKPADDAGLV, first synthesized at the University of Zagreb in the early 1990s from a fragment of a gastric juice protein. It is notably stable in that environment. Its mass is about 1419.5 g/mol.

The research is mostly preclinical: a 2025 systematic review of its use in sports medicine included 36 studies, 35 of them in animals or cells and only 1 clinical. A 2026 review counts fewer than 30 people across three uncontrolled pilot studies.

What TB-500 is

"TB-500" is not an official name. FDA and anti-doping laboratories identify it as the acetylated 17-23 fragment of thymosin beta-4 (Ac-LKKTETQ, about 889 g/mol). Full thymosin beta-4 is a 43-amino-acid protein that binds actin and takes part in cell movement.

The problem is that not everything sold as TB-500 is the same: an analysis of products sold online found contents that did not match their description, and some contain the full protein (about 4963 g/mol) instead of the fragment. That is why the COA must say which molecule is in the vial.

What BPC-157 and TB-500 are for

Social media calls them "recovery peptides" and their combination the "Wolverine stack". Behind that is research in models: BPC-157 is studied in relation to growth factors, nitric oxide and fibroblast migration; thymosin beta-4 in actin dynamics and cell migration.

What is missing is controlled evidence in people. No controlled BPC-157 trial is published in full in PubMed, and FDA has identified no human exposure data for the TB-500 fragment. The two human studies of thymosin beta-4 used the full protein, not TB-500.

Why they are combined

The BPC-157 + TB-500 blend puts the two peptides in one vial because they are researched in similar areas. There are no published studies of the combination, and no data on whether one affects the other’s stability in the vial. If your research needs to control each one separately, they are available as BPC-157 and TB-500.

FDA and sport status

No approved medicine contains BPC-157 or TB-500. Both were on the agenda of FDA’s compounding advisory committee on July 23, 2026, as candidates for the list of substances compounding pharmacies may use; as of October 2026 FDA had published no decision.

The World Anti-Doping Agency bans BPC-157 and thymosin beta-4 and its fragments, and there are validated methods to detect them in urine.

What to check on the COA

• BPC-157: mass spectrometry with an ion near m/z 1419.7, purity by HPLC and the declared salt form (free or acetate).
• TB-500: the mass should say which molecule it is: about 889 Da for the acetylated fragment or about 4963 Da for the full protein. A peak 42 Da lighter means a non-acetylated fragment.
• Blend: the identity of both components, not a single purity figure.

Each point is explained in how to read a COA.